Compare Amgen, Inc. (AMGN) vs Robinhood Markets, Inc. (HOOD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Robinhood Markets, Inc. — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Robinhood Markets, Inc. trades at $111.7 (market cap $100.52B). The key difference: Amgen, Inc. is the larger of the two by market cap, and Amgen, Inc. pays a 2.77% dividend while Robinhood Markets, Inc. pays none. Which is the better fit depends on your goals.
| AMGN | HOOD | |
|---|---|---|
Market Cap | $196.12B | $100.52B |
Sector | Health | Technology |
52-Week High | $388.16 | $152.46 |
52-Week Low | $271.18 | $65.16 |
Enterprise Value | $241.41B | $101.72B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Robinhood (HOOD) trades at $111.97, down 2.73% on the day, with a bullish technical outlook supported by moving averages and strong support at $109. The company shows robust fundamentals with 2025 revenue of $4.47 billion and net income of $1.88 billion, though valuation ratios remain elevated with a P/E of 54.35. Recent news highlights growth initiatives including a Trump Accounts program and AI integration in fintech.
Outlook remains positive with 73% analyst buy ratings and a $112.44 consensus target, but risks include high valuation sensitivity and competitive pressures. Earnings momentum is key, with Q2 2026 results expected to drive near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Robinhood Markets, Inc.
Robinhood Markets, Inc. operates a financial services platform. The Company offers brokerage and cash management applications such as stocks, exchange-traded funds, options, and cryptocurrency. Robinhood Markets serves clients in the United States.
Read more on HOOD →
